Investor Relations

<< Back

Press Release

April 30, 2019 at 4:05 PM EDT

Anika Appoints Stephen Goldy as Vice President of U.S. Sales

Seasoned commercial leader to oversee hybrid commercial organization and upcoming launch of Bone Repair Surgical Therapy in the U.S.

BEDFORD, Mass.--(BUSINESS WIRE)--Apr. 30, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of Stephen Goldy to the newly created position of Vice President of U.S. Sales. Mr. Goldy brings over 20 years of experience developing and implementing sales strategy, with a specialization in the orthopedic, sports medicine and general surgery markets. In this new role, Mr. Goldy will oversee sales strategy and operations for the Company’s hybrid commercial organization in the United States.

“Stephen is an important addition to our team as we establish and execute our new hybrid commercial organization in the U.S.,” said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics. “Stephen brings more than two decades of sales experience and a deep understanding of the orthopedic surgery and sports medicine markets, which will be critical to our near- and long-term growth. We look forward to benefitting from his knowledge and expertise as we prepare for the launch of our first surgically-delivered regenerative therapy for bone repair procedures in the U.S. in the second half of this year. His proven track record of defining and exceeding sales targets and cultivating and managing national accounts will be invaluable as we transform Anika into a global commercial company.”

“I am very excited to join Anika at this transformational time in its evolution and look forward to developing and implementing its hybrid commercial model in advance of the upcoming launch of the Company’s bone repair product in the U.S.,” said Stephen Goldy, Vice President of U.S. Sales at Anika Therapeutics. “Anika’s deep orthopedic and regenerative medicine pipeline and solid reputation for high-quality, innovative treatments positions the company for its next phase of growth.”

Prior to joining Anika, Mr. Goldy spent seven years at ConMed Orthopedics, a global medical device manufacturer, as Regional Vice President and Director of Sales. Before joining ConMed, Mr. Goldy served as National Accounts Manager for Creekridge Capital, a privately-held equipment leasing company, and Global Financial Services Manager at Smith and Nephew. Mr. Goldy holds a Master of Business Administration and Bachelor of Science from the University of Massachusetts.

About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic and regenerative medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika's orthopedic medicine portfolio includes ORTHOVISC®MONOVISC®, and CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit

Source: Anika Therapeutics, Inc.

For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer

For Media Inquiries:
W2O Group
Sonal Vasudev, 917-523-1418